

Fig. (2). Rationale of personalized peptide vaccine. In conventional peptide vaccines without pre-existing immunity, patients without immunological memory to vaccine antigens would take more time to develop effective anti-tumor immune responses because several rounds of repeated vaccinations might be required to prime antigen-specific naive T cells to functional effector cells. In personalized peptide vaccines with the pre-existing immunity, patients with antigen-specific immunological memory are expected to show quick and strong secondary immune responses to them.

clinical benefits, especially in advanced cancer patients who show rapid disease progression [26]. In light of this, it would be quite reasonable to select vaccine antigens on the basis of the pre-existing immune cell repertoires in each patient.

Cancer cells can develop various mechanisms to accelerate malignant behavior [21]. For example, it has been well recognized that cancer cells might escape the host's immunological surveillance. After the interaction/competition between tumor cells and host immune cells, tumor cell variants resistant to the immunological pressure often emerge through the selection of mutants with reduced antigenicity [21]. Therefore, the selection and administration of multiple vaccine antigens could reduce the risk of tumor escape through the existence and/or induction of antigen-negative variants escaping antigen-specific immune responses [22, 27], since it would be rare for tumor cells to simultaneously lose all of the multiple antigens selected for vaccination.

Collectively, our new concept of "personalized" cancer vaccine formulation, where multiple peptide antigens are selected for vaccination by the pre-existing host immunity from a list of vaccine candidates, may confer several advantages, including the possibility of bypassing both immunological diversity and tumor heterogeneity.

2.2. PPV Procedures

For PPV, a maximum of four peptides are selected based on the results of HLA typing and the pre-existing immune responses specific to each of the 31 HLA class I-restricted cytotoxic T lymphocyte (CTL) epitope peptides with minimal optimal lengths (9-mer or 10-mer): 12 peptides for HLA-A2, 14 peptides for HLA-A24, 9 peptides for HLA-A3 supertype (A3, A11, A31, or A33), and 4 peptides for HLA-A26 (Table **1**). These peptides were identified mainly through the cDNA expression cloning method with tumor-infiltrating T-lymphocyte lines [25, 28-34]. The safety and potential immunological effects of these vaccine candidates have been demonstrated in clinical studies [25, 35, 36]. It should be noted that we currently employ these 31 CTL epitopes, which are also shown to induce antigen-specific B-cell immune responses, as vaccine antigen candidates for PPV, since it has been suggested that a CTL peptide with the ability to induce antigen-specific B-cell responses could provide more effective immune responses than a CTL peptide without it [37, 38].

Although short peptide epitopes with minimal optimal lengths have been reported to bear the potential to induce immune tolerance rather than activate antigen-specific immune responses [39-41], our PPV formulation with short epitopes has been demonstrated to efficiently induce antigen-specific IFN-γ-producing $CD8^+$ T cells, but not tolerance to them, possibly because only immunogenic epitopes are selected in each patient by screening before vaccination. Although long synthetic peptides have shown excellent immune responses and promising clinical results in some clinical trials [42, 43], we do not currently use long peptides for PPV, since they may contain undesirable T-cell epitopes that activate other immune cells, such as T helper 2 cells and/or regulatory T cells [44, 45], which could negatively affect beneficial antigen-specific immune responses.

Different peptides have their own different binding affinities to the corresponding HLA molecules. Therefore, if multiple CTL-epitope peptides with different HLA-binding affinities are loaded to APCs, the individual peptides may compete with each other to bind HLA molecules on the APCs [46]. For PPV, to prevent such competition among peptides at the vaccinated sites, a maximum of 4 immunogenic peptides selected from the 31 different vaccine candidates are individually mixed with incomplete Freund's adjuvant (Montanide ISA51; Seppic, Paris, France) and subcutaneously injected at different sites, but not at a single site as a mixture. Regarding the vaccination schedule,

Table 1. Peptide candidates used for personalized peptide vaccine (PPV).

Peptide Name	HLA Restriction	Original Protein	Position	Amino Acid Sequence
CypB-129	A2 A3sup	Cyclophilin B	129-138	KLKHYGPGWV
EGFR-800	A24	EGF-R	800-809	DYVREHKDNI
EZH2-735	A24	EZH2	735-743	KYVGIEREM
HNRPL-140	A2	HNRPL	140-148	ALVEFEDVL
HNRPL-501	A2 A26	HNRPL	501-510	NVLHFFNAPL
Lck-90	A3sup	p56 lck	90-99	ILEQSGEWWK
Lck-208	A24	p56 lck	208-216	HYTNASDGL
Lck-246	A2	p56 lck	246-254	KLVERLGAA
Lck-422	A2 A3sup	p56 lck	422-430	DVWSFGILL
Lck-449	A3sup	p56 lck	449-458	VIQNLERGYR
Lck-486	A24	p56 lck	486-494	TFDYLRSVL
Lck-488	A24	p56 lck	488-497	DYLRSVLEDF
MAP-432	A2 A26	ppMAPkkk	432-440	DLLSHAFFA
MRP3-503	A24	MRP3	503-511	LYAWEPSFL
MRP3-1293	A24	MRP3	1293-1302	NYSVRYRPGL
PAP-213	A24	PAP	213-221	LYCESVHNF
PAP-248	A3sup	PAP	248-257	GIHKQKEKSR
PSA-248	A24	PSA	248-257	HYRKWIKDTI
PSMA-624	A24	PSMA	624-632	TYSVSFDSL
PTHrP-102	A24	PTHrP	102-111	RYLTQETNKV
SART2-93	A24	SART2	93-101	DYSARWNEI
SART2-161	A24	SART2	161-169	AYDFLYNYL
SART3-109	A24 A3sup A26	SART3	109-118	VYDYNCHVDL
SART3-302	A2	SART3	302-310	LLQAEAPRL
SART3-309	A2	SART3	309-317	RLAEYQAYI
SART3-511	A3sup	SART3	511-519	WLEYYNLER
SART3-734	A3sup	SART3	734-742	QIRPIFSNR
UBE-43	A2	UBE2V	43-51	RLQEWCSVI
UBE-85	A2	UBE2V	85-93	LIADFLSGL
WHSC2-103	A2 A3sup A26	WHSC2	103-111	ASLDSDPWV
WHSC2-141	A2	WHSC2	141-149	ILGELREKV

A3sup: HLA-A3 supertype (A3, A11, A31, or A33); EGF-R: Epidermal Growth Factor Receptor; EZH2: enhancer of zeste homolog 2; HNRPL: heterogeneous nuclear ribonucleoprotein L; ppMAPkkk: partial putative mitogen-activated protein kinase kinase kinase; MRP3: multidrug resistance-associated protein 3; PAP: Prostatic acid phosphatase; PSA: prostate specific antigen; PSMA: Prostate specific membrane antigen; PTHrP : parathyroid hormone-related peptide; SART2: squamous cell carcinoma antigen recognized by T cells 2; SART3: squamous cell carcinoma antigen recognized by T cells 3; UBE2V: ubiquitin-conjugated enzyme variant Kua; WHSC2: Wolf-Hirschhorn syndrome candidate 2.

the selected peptides are administered weekly for at least the first cycle of six vaccinations, since a clear trend toward better immune responses was observed among the patients who underwent the weekly administration protocol compared to those who underwent a bi-weekly protocol in our previous clinical trials [47].

One of the noticeable characteristics of our PPV formulation is that it screens vaccine antigen candidates before vaccination, based on CTL-precursor frequencies and/or immunoglobulin G (IgG) titers specific to each of the candidates in pre-vaccination blood samples from each patient [25]. In the earlier stage of translational studies of PPV, pre-existing immunity was defined by the frequencies of CTL precursors in pre-vaccination peripheral blood mononuclear cells (PBMC) by detecting peptide-specific IFN-γ production by enzyme-linked immunosorbent assay (ELISA) [47-51]. However, we are currently evaluating the pre-existing im-

munity to vaccine candidates by measuring peptide-specific IgG titers in pre-vaccination plasma by the multiplex bead-based Luminex assay rather than CTL precursor frequencies, since the performance characteristics, such as the sensitivity and reproducibility, of the current T-cell assays are sometimes unsatisfactory for detecting low frequencies of antigen-specific CTL [52, 53]. In contrast to the drawbacks inherent to T-cell assays, the multiplex bead-based Luminex technology that we have developed to monitor B-cell responses allows simple, quick, and highly reproducible high-throughput screening and monitoring of IgG responses specific to a large number of peptide antigens with a tiny amount of plasma [36, 54, 55]. Indeed, the selection of vaccine antigens based on IgG titers seemed to be useful for predicting CTL boosting after vaccination in our clinical trials. The predictive power of evaluating the existence of antigen-specific CTL precursors solely by the humoral responses before vaccination could be estimated at around 50% when four peptides were chosen for PPV in each patient [56, 57].

2.3. Clinical Trials of PPV for Advanced Cancers

A series of phase I, I/II, and II clinical trials of PPV has been conducted in the past several years for various types of advanced cancer patients. Table **2** summarizes the immune and clinical responses of advanced cancer patients treated with PPV. In the following sections, we provide some detailed information on these clinical studies.

2.3.1. Castration-Resistant Prostate Cancer (CRPC)

In phase I studies of PPV for advanced HLA-A2$^+$ or HLA-A24$^+$ CRPC, we have reported increased cellular and humoral immune responses and decreased PSA levels in some patients [58, 59]. In a phase I dose-escalation study of PPV (1, 3, and 5 mg/peptide injection) for HLA-A24$^+$ CRPC, we have also demonstrated that a dose of 3 mg/peptide injection showed better cellular immune responses to vaccine peptides than either 1 or 5 mg/peptide injections, although the maximum tolerated dose (MTD) was not determined [56]. In addition, in a phase I/II study of 58 HLA-A2$^+$ or HLA-A24$^+$ CRPC patients, a combination of PPV and low-dose estramustine phosphate (EMP) showed a median survival time (MST) of 17 months (95% confidence interval (95% CI), 12 to 25 months), along with a decreased serum PSA level in the majority (76%) of patients [60]. The same study also revealed that fewer lymphocytes, negative immunological responses to vaccine antigens, and poor performance status were independent predictors of disease-related death [60].

Subsequently, we conducted a randomized phase II trial to compare PPV plus low-dose EMP with standard-dose EMP in HLA-A2$^+$ or HLA-A24$^+$ CRPC patients. The patients receiving PPV in combination with low-dose EMP showed a significantly longer progression-free survival [MST, 8.5 months vs 2.8 months; hazard ratio (HR), 0.28 (95% CI, 0.14-0.61); P = 0.0012] and overall survival [MST, undefined vs 16.1 months; HR, 0.30 (95% CI, 0.1-0.91); P = 0.0328] than those receiving standard-dose EMP alone, suggesting the efficacy of this combination therapy [61]. In another phase II study, we compared docetaxel-based chemotherapy (DBC)-resistant CRPC patients undergoing PPV (n =20) with a historical control (n = 17). MSTs from the failure of previous DBC treatments were 17.8 and 10.5 months in patients treated with and without PPV, respectively [62]. These promising results suggested that PPV warrants further study as a novel therapy for CRPC patients, even for those with progressive disease following DBC treatment. A phase III randomized clinical trial of PPV is currently under way in DBC-resistant CRPC patients.

2.3.2. Malignant Glioma

In a phase I clinical study, we demonstrated the feasibility of PPV for HLA-A2$^+$ or HLA-A24$^+$ advanced malignant glioma patients [47]. The clinical responses of 27 patients who received more than six vaccinations were partial response (PR) in 5, stable disease (SD) in 8, and progressive disease (PD) in 8 patients, with a MST of 20.7 months. Significant levels of IgG specific to vaccine peptides were detected after vaccination in the tumor cavity or spinal fluid obtained from patients who had shown favorable clinical responses. Another phase I clinical trial in HLA-A24$^+$ patients with recurrent or progressive GBM also showed the safety and increased immune boosting of PPV with potential clinical benefits, with a MST of 10.6 months even after failure of the standard temozolomide treatment [57]. On the basis of these promising results, double-blind randomized phase III trials are under way in GBM patients resistant to the standard treatment.

2.3.3. Pancreatic Cancer and Biliary Tract Cancer

We have conducted a phase I trial of PPV in 13 HLA-A2$^+$ or HLA-A24$^+$ patients with advanced pancreatic cancer, where the patients were treated by PPV at three different doses (1, 2, or 3 mg/peptide) in combination with gemcitabin (GEM) [63]. This combination therapy was well tolerated, and 11 of 13 patients (85%) showed reduced tumor sizes and/or levels of tumor markers. Peptide-specific CTL responses were augmented at each dose level, and the increment of peptide-specific IgG antibodies was dependent on the peptide dose. These findings suggested that GEM did not inhibit the immune responses induced by PPV. Subsequently, we conducted a phase II trial of PPV in combination with GEM to evaluate the safety, clinical efficacy, and antigen-specific immune responses as a front-line therapy for 21 HLA-A2$^+$ or HLA-A24$^+$ nonresectable patients with advanced pancreatic cancer [64]. This combination therapy was also well tolerated, and the best clinical responses were PR in 7, SD in 9, and PD in 5 patients. The MST of all 21 patients was 9 months with a 1-year survival rate of 38%, which was better than that reported for GEM alone (MST of 5.7 months with a 1-year survival rate of 18%) [65]. Importantly, the MST was 15 months in patients who showed immunological responses to vaccine peptides.

We also conducted a phase II clinical trial of PPV in 25 HLA-A2$^+$ or HLA-A24$^+$ chemotherapy-resistant patients with advanced biliary tract cancer [66]. When two to four vaccine peptides selected by pre-existing immunity were administered to the patients in this study, humoral and/or T-cell responses specific to the vaccine antigens were substantially induced in a subset of the patients without severe adverse events. Greater numbers of selected and vaccinated peptides were significantly favorable factors for overall survival (HR = 0.258, 95% CI = 0.098-0.682, P = 0.006) in this study (Table **3**).

Table 2. List of clinical trials of personalized peptide vaccines (PPV) for advanced cancer.

Organ	Disease condition	Phase of trial	HLA restriction	Combined treatment	No. of Patients	Clinical response	MST (months)	Toxicities (Grade 3/4)	Humoral response (%)	Cellular response (%)	Refer-ence
Prostate (CRPC)	Advanced	I	A24	-	10	SD 50%	NA	-	60	40	[58]
Prostate (CRPC)	Advanced	I	A24	EMP	13	PR 63%	24	G3, 5%	91	55	[114]
Prostate (CRPC)	Advanced	I	A2	-	10	SD 30%	22	-	70	40	[59]
Prostate (CRPC)	Advanced	I/II	A24	EMP	16	PR 43%	17	-	50	71	[115]
Prostate (CRPC)	Advanced	I/II	A2/A24	EMP	58	PR 24%	17	G3, 7%	88	78	[60]
Prostate (CRPC)	Advanced	I	A24	EMP	15	PR 13%	24	-	47	67	[56]
Prostate (CRPC)	Advanced	II (Ran-domized)	A2/A24	EMP	57	8.5M vs 2.8M (PFS)	22.4M vs 16.1M	-	64	50	[61]
Prostate (CRPC)	Advanced	II	A2/A24/ A3sup/A26	-	42	PR 12%	17.8	-	44	34	[62]
Prostate	Localized	II	A24	-	10	PR 20%	NA	-	80	80	[116]
Brain	Advanced malignant glioma	I	A2/A24	-	21	PR 24%, SD 38%	NA	-	40 - 64	50 - 82	[47]
Brain	Advanced GBM	I	A24	-	12	PR 17%, SD 42%	10.6	-	17	75	[57]
Pancreas	Advanced	I	A2/A24	GEM	13	PR 15%, SD 54%	7.6	-	69	69	[63]
Pancreas	Advanced	II	A2/A24	GEM	21	PR 33%, SD 43%	9	-	72	78	[64]
Biliary tract	Advanced	II	A2/A24/ A3sup/A26	Chemo-therapy	25	SD 32%	NA	G3, 4%	35	47	[66]
Stomach	Advanced	I	A2/A24	-	13	SD 45%	NA	-	80	50	[67]
Stomach Colorectal	Advanced	I/II	A2/A24	S-1	11	SD 36%	NA	G3, 18%	81	63	[69]
Colorectal	Advanced	I	A24	-	10	PR 10%	NA	-	70	50	[68]
Colorectal	Metastatic	I	A2/A24	UFT UZEL	13	SD 43%	19.6	G3, 7.7%	69	85	[70]
Lung	Advanced	I	A24	-	10	SD 80%	15.2	-	40	40	[50]
Lung	Advanced (NSCLC)	II	A2/A24 A3sup/A26	Chemo-therapy	41	SD 56%	10.1	G3, 7%	49	34	[71]
Lung	Advanced (SCLC)	II	A2/A24 A3sup/A26	Chemo-therapy	10	SD 20%	6.2	G3, 4%	83	83	[72]

(Table 2) contd....

Organ	Disease condition	Phase of trial	HLA restriction	Combined treatment	No. of Patients	Clinical response	MST (months)	Toxicities (Grade 3/4)	Humoral response (%)	Cellular response (%)	Reference
Urothelial	Advanced	I	A2/A24	-	10	CR 10%, PR 10%	24	-	80	80	[73]
Kidney	Metastatic	I	A2/A24	-	10	SD 60%	23	-	80	5	[74]
Uterine, Ovary	Recurrent	I	A2/A24	-	14	SD 36%	NA	G3, 8%	86	86	[49]
Skin	Malignant melanoma	I	A2/A24	-	7	SD 43%	NA	-	57	86	[51]

CRPC: castration-resistant prostate cancer; GBM: glioblastoma multiforme; SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; A3sup: HLA-A3 supertype (A3, A11, A31, or A33); EMP: estramustine phosphate; GEM: gemcitabine; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; PFS: progression-free survival; MST: median survival time; NA: not assessed; M: months.

Table 3. Biomarkers for personalized peptide vaccines (PPV) for advanced cancer.

Type of cancer	Factor	Statistical analysis (HR, 95% CI, P value)	Reference
Miscellaneous (n = 500)[a]	Performance status (1, 2, 3 vs 0) Lymphocyte counts (<1500μL vs > 1500μL) IgG responses to antigens after vaccination (no vs yes)	HR = 2.295; 95% CI, 1.653 - 3.188; P < 0.0001 HR = 1.472; 95% CI, 1.099 - 1.972, P = 0.0095 HR = 1.455; 95% CI, 1.087 - 1.948, P = 0.0116	[36]
Prostate (CRPC, n = 40)	IL-6 MDSC	(Not determined) (Not determined)	[81]
Non-small lung cell cancer (n =41)[a]	C-reactive protein (CRP)	HR = 10.115, 95% CI = 2.447 – 41.806, P = 0.001	[71]
Biliary tract (n = 25)[a]	IL-6 Albumin Numbers of vaccine peptides	HR = 1.123, 95% CI = 1.008 -1.252, P = 0.035 HR = 0.158; 95% CI, 0.029 - 0.860; *P* = 0.033 HR = 0.258, 95% CI = 0.098-0.682, *P* = 0.006	[66]

[a]Potential biomarkers for PPV were determined by multivariate Cox regression analyses.; HR: hazard ratio; CI: confidence interval; CRPC: castration-resistant prostate cancer; MDSC: myeloid-derived suppressor cells.

2.3.4. Gastric Cancer and Colorectal Cancer

In a phase I clinical trial of PPV in 13 HLA-A2$^+$ or HLA-A24$^+$ patients with advanced gastric cancer (9 nonscirrhous and 4 scirrhous), prolonged survival was observed in patients who showed cellular and humoral immune responses to the vaccine peptides in the post-vaccination blood samples, including all 4 patients with the scirrhous type [67]. In addition, a phase I clinical trial of PPV in 10 HLA-A24$^+$ patients with advanced colorectal cancer showed one PR and one SD, each continuing for more than 6 months [68].

In a phase I/II clinical trial of PPV in combination with three different doses (20, 40, or 80 mg/m^2/day) of oral administration of a 5-fluorouracil derivative, S-1, for 11 HLA-A2$^+$ or HLA-A24$^+$ advanced gastric or colorectal cancer patients [69], the combined administration of the standard dose (80 mg/m^2/day) of S-1 did not inhibit immunological responses to vaccine antigens, but instead maintained or augmented them. In another phase I clinical trial for 13 HLA-A2$^+$ or HLA-A24$^+$ metastatic colorectal cancer patients [70], the combined treatment of PPV and the oral administration of a 5-fluorouracil derivative, UFT, and calcium folinate, UZEL, proved to be safe and to induce good antigen-specific immune responses. In this trial, IgG responses to the vaccine peptides correlated well with overall survival. These encouraging results suggest that combined treatment with PPV and standard chemotherapeutic agents might be promising for advanced gastric and colorectal cancers.

2.3.5. Lung Cancer

The prognosis of advanced lung cancer patients remains very poor, with a MST of around 6-10 months. Phase I and II studies of PPV in a small number of patients with refractory NSCLC demonstrated that PPV was safe and well tolerated,

with no major adverse effects, and that PPV treatment resulted in longer survival (MST of 10.1 or 15.2 months) [50, 71]. A clinical study in 10 advanced small cell lung cancer (SCLC) also showed the safety and feasibility of PPV [72].

2.3.6. Urothelial Cancer

A phase I clinical trial of PPV was conducted in 10 HLA-A2$^+$ or HLA-A24$^+$ refractory urothelial cancer patients [73]. In this study, some patients treated by PPV showed clear clinical responses as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria with boosted immune responses: CR in 1, PR in 1, and SD in 2 patients. These 4 responders showed better progression-free survival (MST, 21 months) and overall survival (MST, 24 months), suggesting the potential clinical efficacy of PPV for advanced urothelial cancer.

2.3.7. Other Cancers

We also conducted phase I clinical trials for other advanced cancers, including metastatic renal cell carcinoma (RCC) [74], gynecologic cancers [49], and malignant melanoma [51]. All of these studies demonstrated that PPV was safe and well tolerated with no major adverse effects, and that good immune responses to vaccine antigens were induced in many of the patients after PPV. Further clinical trials would be required to clearly prove the clinical benefits of PPV in these cancers.

2.4. Biomarkers for PPV (Table 3)

Recent clinical trials of cancer immunotherapies, including peptide-based cancer vaccines, have demonstrated that only a subset of patients show clinical benefits. Furthermore, unexpectedly, some large clinical trials in the past several years have demonstrated that cancer vaccines might sometimes show worse clinical outcomes [75, 76]. It would thus be important to identify predictive biomarkers that could accurately assess anti-tumor immune responses and predict patient prognosis following the administration of cancer vaccines. In some clinical trials, several post-vaccination biomarkers, including CTL responses, Th1 responses, delayed-type hypersensitivity (DTH), and autoimmunity, have been reported to be associated with clinical responses.[77-80]. However, there are currently no validated biomarkers for cancer vaccines in widespread use.

To identify biomarkers for PPV, we statistically reviewed 500 advanced cancer patients undergoing PPV from October 2000 to October 2008 [36]. Both lymphocyte counts before vaccination (P = 0.0095) and increased IgG response (P = 0.0116) to the vaccine peptides after vaccination, along with performance status (P < 0.0001), were well correlated with overall survival. In CRPC patients treated with PPV (n = 40), a comprehensive study of soluble factors assessed by multiplexed bead array in plasma and gene expression profiles by DNA microarray in PBMC demonstrated that higher IL-6 level and granulocytic myeloid-derived suppressor cells (MDSC) in the peripheral blood before vaccination were closely related to poorer prognosis in the vaccinated patients [81]. By multivariate Cox regression analyses in patients with refractory NSCLC (n = 41), higher C-reactive protein (CRP) level before vaccination was a significant predictor of unfavorable overall survival (HR = 10.115, 95% CI = 2.447 – 41.806, P = 0.001) [71]. In addition, in refractory biliary tract cancer patients (n = 25), multivariate Cox regression analyses showed that higher IL-6 and lower albumin levels before vaccination were significantly unfavorable factors for overall survival [HR = 1.123, 95% CI = 1.008 - 1.252, P = 0.035; HR = 0.158, 95% CI = 0.029 - 0.860, P = 0.033; respectively] [66].

Collectively, these findings suggested that less inflammation may contribute to better responses to PPV, indicating that the evaluation of inflammatory factors before vaccination could be useful for selecting cancer patients who are appropriate for PPV (Table **3**). An early phase clinical trial is under way to reveal whether or not the blockage of IL-6-mediated inflammatory signaling with a humanized anti-IL-6 receptor monoclonal antibody, tocilizumab, would be beneficial for enhancing the immune and/or clinical responses after PPV in advanced cancer patients who show higher plasma IL-6 levels [82, 83].

3. OTHER NEW TYPES OF PEPTIDE VACCINES

Recent early phase clinical trials have also demonstrated significant advances in other types of therapeutic peptide-based vaccines [19, 20]. Several new types of peptide-based vaccines are reviewed in this section (Fig. **1**).

3.1. Multi-Peptide Vaccine Consisting of CTL and Helper T-Cell Epitopes

Numerous helper T-cell epitopes have been identified from TAA. Since helper T cells are known to play crucial roles in the efficient induction of CTL responses, cancer vaccines, which consist of both HLA class II-restricted helper epitopes recognized by CD4 T cells and class I-restricted CTL epitopes recognized by CD8 T cells, have been developed and clinically tested [84-89]. For example, Kuball *et al.* conducted a phase I study of a multi-peptide vaccine consisting of multiple CTL epitopes from Wilms tumor gene-1 (WT-1), proteinase 3 (Pr3) and mucin 1 (MUC1), and MUC1-helper epitope or pan HLA-DR epitope (PADRE) [84]. Each peptide was formulated separately and injected at a different site. In this study, an increase in PADRE-specific CD4 T cells, which appeared unable to produce IL2, was observed after vaccination, and regulatory T cells were increased, suggesting that helper epitope peptides have the potential to induce not only helper T cells but also regulatory T cells. Krug *et al.* tested the safety and immunogenicity of a WT1 vaccine comprised of four class I and class II-restricted peptides in patients with malignant pleural mesothelioma or NSCLC expressing WT1 [85]. They showed that this multivalent WT1 peptide vaccine induced both CD4 and CD8 T-cell responses in a high proportion of patients with minimal toxicity.

3.2. Multi-Peptide Cocktail Vaccine

If each of multiple peptides are formulated separately and injected at a separate site, the number of peptides employed for vaccination might be limited. One strategy for overcoming this limitation is to generate multi-peptide cocktail vaccines, since one preparation could contain more than 10 different peptides. Although the issue of competition between

individual peptides to bind to HLA molecules on the APCs still remains [46], different types of multi-peptide cocktail vaccines have been developed; vaccines consisting of CTL epitope peptides alone [90, 91] or those of both CTL epitope and helper epitope peptides [86-89].

Barve *et al.* conducted a phase I/II study of a multi-peptide cocktail vaccine, IDM-2101, consisting of nine CTL epitope peptides and the PADRE helper epitope peptide with Montanide ISA51 in patients with metastatic non-small cell lung cancer [86]. No significant adverse events were noted except for low-grade erythema and pain at the injection site. One-year survival in the treated patients was 60%, with a median overall survival of 17.3 months. One complete response (CR) patient was observed in the total of 63 patients. Slingluff *et al.* conducted a multicenter randomized trial to examine the immunogenicity of a multi-peptide cocktail vaccine containing 12 melanoma-associated HLA class I-restricted peptides (12MP) for $CD8^+$ T cells and tetanus peptide or a mixture of six melanoma-associated helper peptides (6MHP) for $CD4^+$ T cells in the presence or absence of cyclophosphamide pretreatment in 167 patients with resected stage IIB to IV melanoma [87]. However, the combination of 6MHP with 12MP paradoxically reduced the circulating $CD8^+$ T-cell response, and cyclophosphamide pretreatment had no measurable effect on $CD8^+$ or $CD4^+$ responses. Clinical outcome was not improved by adding melanoma-associated helper peptides or by adding cyclophosphamide.

Rammensee and his colleagues also reported a phase I/II trial of a multi-peptide cocktail vaccine, which consisted of 13 synthetic peptides (11 HLA-A*0201-restricted CTL epitopes and 2 helper epitopes derived from prostate tumor antigens) for 19 $HLA\text{-}A2^+$ hormone-sensitive prostate cancer patients with biochemical recurrence after primary surgical treatment [88]. The vaccine was well tolerated, and stabilized or slowed down PSA progress in 4 of the 19 patients. The same group also developed another cocktail vaccine, IMA901, which consisted of nine HLA-A*0201-restricted CTL epitopes and one helper epitope from renal cell cancer antigens with hepatitis B virus epitope as a marker peptide, for advanced renal cell cancer [89]. In a randomized phase II trial with a single dose of cyclophosphamide, the number of regulatory T cells was reduced, and immune responses to the vaccine peptides were associated with longer overall survival. A randomized phase III study to determine the clinical benefit of IMA901 is ongoing.

3.3. Hybrid Peptide Vaccine

Peptides used in most clinical trials for peptide-based vaccines possess native amino acid sequences with or without slight modification in anchor amino acids to increase their binding capability to HLA molecules. However, hybrid-type peptide vaccines, which use a new artificial peptide fusing two or more peptides, have been devised. For example, the Ii-Key/HER-2/neu hybrid peptide vaccine, a fusion peptide made up of the Ii-Key 4-mer peptide and HER-2/neu (776-790) helper epitope peptide, has been reported [92, 93]. The Ii/Key 4-mer peptide is the shortest active sequence of the Ii protein, which catalyzes direct charging of MHC class II epitopes to the peptide-binding groove, circumventing the need for intracellular epitope processing [94]. Phase I studies of the Ii-Key/HER-2/neu hybrid peptide vaccine in patients with prostate cancer showed that this vaccine is safe and can induce HER-2/neu-specific cellular immune responses in vaccinated patients [93]. In addition, significant decreases in circulating regulatory T-cell frequencies, plasma HER2/neu, and serum TGF-beta levels were observed.

Nishimura *et al.* reported an artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP) of MAGE-A4 cancer antigen [95]. In the first case report, a patient with pulmonary metastasis of colon cancer was vaccinated with MAGE-A4-H/K-HELP in combination with OK432 and Montanide ISA51. There were no severe side effects except for a skin reaction at the injection site. Vaccination with MAGE-A4-H/K-HELP induced MAGE-A4-specific Th1 and Tc1 immune responses and the production of MAGE-A4-specific complement-fixing IgG antibodies. Tumor growth and tumor markers were significantly decreased in this patient.

3.4. Long Peptide Vaccine

The classical types of peptide vaccines have consisted of short epitope peptides with minimal optimal lengths, which are recognized by CTLs or helper T cells in an HLA class I- or class II-restricted manner, respectively. However, direct binding of short peptides to nonspecific cells without a co-stimulatory capacity has been reported to bear the potential to induce tolerance to antigen-specific T cells rather than to induce their activation in some mouse models [39-41]. Therefore, a novel approach using synthetic long peptides, which need to be taken up by professional APCs and processed for presentation by HLA class I and/or class II molecules, has been developed for cancer vaccination, although the efficiency and mechanisms of presentation of exogenous long peptides in human HLA class I remain to be fully elucidated [96]. Synthetic long peptides may contain not only HLA class I-restricted but also HLA class II-restricted epitopes, which can activate helper T cells important for the efficient induction of antigen-specific CTL responses.

Several clinical studies using a pool of multiple synthetic long peptides have been reported, since a mixture of multiple synthetic long peptides is likely to contain multiple HLA class I-restricted and class II-restricted T-cell epitopes, which could be applicable to any patients irrespective of their HLA types [42-45, 97-100]. Melief and his colleagues showed that a vaccine composed of a synthetic long peptide pool derived from high-risk-type human papillomavirus (HPV)-16 E6/E7 oncoproteins successfully induced HPV-specific immune responses [42, 43]. They conducted a phase I study of HPV16 E6 and E7 overlapping long peptides in end-stage cervical cancer patients [42]. Cocktails of nine E6 peptides and/or four E7 peptides covering the entire sequences of E6 and E7 proteins showed a strong and broad T-cell response dominated by immunity against E6 after four subcutaneous administrations with Montanide ISA51 at 3-week intervals. Subsequently, they conducted a phase II study of the same vaccine in patients with HPV-positive grade 3 vulvar intraepithelial neoplasia, which is a chronic disorder caused by HPV [43]. At 3 months after the last vaccination, 12 of 20 patients (60%) had clinical responses and reported relief of symptoms. Five women had complete regression of the lesions. At 12 months of follow-up, 15 of 19

patients (79%) had clinical responses, with a complete response in 9 of 19 patients (47%).

The same group also reported a synthetic long peptide vaccine targeted for p53. This p53 synthetic long peptide vaccine (p53-SLP) consisted of 10 synthetic 25-mer to 30-mer long overlapping peptides, spanning amino acids 70–248 of the wild-type p53 protein. In a phase I/II trial of the p53-SLP vaccine in 10 patients with metastatic colorectal cancer, p53-specific T-cell responses were induced in 9 of 10 patients as measured by IFN-γ enzyme-linked immunospot (ELISPOT), proliferation, and cytokine bead arrays [97]. Subsequently, a phase II study of the same vaccine in 20 ovarian cancer patients with recurrent elevation of CA-125 showed that SD, as determined by CA-125 levels and CT scans, was observed in 2 out of 20 patients (10%) as the best clinical response, but no relationship was found between the clinical response and vaccine-induced immunity [44]. IFN-γ–producing p53-specific responses were induced in CD4 T cells, but not in CD8 T cells, in all patients who received four immunizations. The absence of p53-specific CD8 T-cell responses might be attributable to the dominant production of Th2 cytokines by CD4 T cells, which have inhibitory effects on CTL induction. Nevertheless, the combined use of p53-SLP vaccine and a low dose of cyclophosphamide or IFN-α has recently been reported to efficiently induce more IFN-γ–producing p53-specific T cells, suggesting that these combinations may potentiate the immunogenicity of the p53-SLP vaccine [98, 99].

Kakimi *et al.* also conducted a phase I trial of an NY-ESO-1 synthetic long peptide vaccine. A 20-mer peptide spanning from amino acid 91 to 110 of NY-ESO-1, called NY-ESO-1f, which includes multiple epitopes recognized by antibodies and CD4 and CD8 T cells, was administered along with OK-432 and Montanide ISA51 to patients with advanced cancers [100]. Both antigen-specific CD4 and CD8 T-cell responses, as well as antibody responses, were increased in 9 of 10 patients.

3.5. Novel Approach for Targeting Peptides to Professional APCs

The goal of cancer immunotherapy is to induce and amplify functional antigen-specific immune responses in order to develop long-lasting immunological memory specific to tumor cells [101, 102]. However, one hurdle to the use of peptide-based vaccines is that the uptake and/or presentation of vaccine peptides by nonspecific cells, but not by professional APCs, leads to CTL anergy through insufficient stimulation [103]. For efficient priming and activation of antigen-specific CTL through vaccination, sufficient amounts of antigens should be presented to T cells by functionally activated, professional APCs for sufficient periods of time [104-107]. In this respect, a novel delivery system for peptide vaccines remains to be developed.

For example, nanotechnology-based antigen delivery has been developing as a vaccine strategy due to its dose-sparing and prolonged antigen presentation features [108, 109]. In particular, polymeric nanoparticles (NP) have attracted increasing attention as carriers of therapeutic immunogens [110]. Antigen peptides encapsulated in polymeric NP are shown to be directly and specifically delivered to professional APCs via phagocytosis without proteolytic degradation, and efficiently cross-presented to induce strong T-cell immunity, whereas those in solution that are internalized by APCs via macropinocytosis are reported to be poorly presented as peptides in complex with MHC class I molecules on cell surfaces [111, 112]. Indeed, we have demonstrated the feasibility of NP consisting of a biodegradable, biocompatible copolymer, poly(D,L-lactide-co-glycolide) (PLGA) carrying antigenic peptides and a toll-like receptor 4 agonist, monophosphoryl lipid A, to efficiently induce CTL responses against TAA in murine tumor models [113]. To increase the efficacy of peptide-based vaccines, such a novel antigen delivery system remains to be developed and clinically examined.

CONCLUSIONS

In the field of cancer immunology and immunotherapy, excitement and enthusiasm have risen around the latest approvals of immunotherapy-based treatments in various cancer types. However, several issues remain to be addressed in order to achieve further development of cancer vaccines. In particular, in view of the complexity and diversity of tumor cell characteristics and host immune cell repertoires, the selection of vaccine peptides appropriate for individual patients based on the pre-existing host immunity before vaccination could be critical for the efficient induction of beneficial antitumor responses in cancer patients. In a series of clinical trials, we have demonstrated promising results of PPV as a new treatment modality for patients with various types of advanced cancer. Further randomized phase III clinical trials are essential to validate the clinical benefits of PPV. Moreover, novel biomarkers for selecting patients who would benefit most from PPV remain to be addressed.

CONFLICT OF INTEREST

Akira Yamada is an Executive Officer for Green Peptide Company, Ltd. Kyogo Itoh received a research grant from the Green Peptide Company, Ltd. and owns stock in the Green Peptide Company, Ltd.

ACKNOWLEDGEMENTS

This study was supported by the grants from the Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Sendai-Kousei Hospital.

REFERENCES

[1] Finn, O.J. Cancer immunology. *N. Engl. J. Med.*, **2008**, *358*(25), 2704-2715.

[2] Rosenberg, S.A. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. *Nat. Rev. Clin. Oncol.*, **2011**, *8*(10), 577-585.

[3] Mellman, I.; Coukos, G.; Dranoff, G. Cancer immunotherapy comes of age. *Nature*, **2011**, *480*(7378), 480-489.

[4] Schlom, J. Therapeutic cancer vaccines: current status and moving forward. *J. Natl. Cancer Inst.*, **2012**, *104*(8), 599-613.

[5] Itoh, K.; Yamada, A.; Mine, T.; Noguchi, M. Recent advances in cancer vaccines: an overview. *Jpn. J. Clin. Oncol.*, **2009**, *39*(2), 73-80.

[6] Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; Xu, Y.; Frohlich, M.W.; Schellhammer, P.F. IMPACT Study

Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N. Engl. J. Med.*, **2010**, *363*(5), 411-422.

[7] Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; Akerley, W.; van den Eertwegh, A.J.; Lutzky, J.; Lorigan, P.; Vaubel, J.M.; Linette, G.P.; Hogg, D.; Ottensmeier, C.H.; Lebbé, C.; Peschel, C.; Quirt, I.; Clark, J.I.; Wolchok, J.D.; Weber, J.S.; Tian, J.; Yellin, M.J.; Nichol, G.M.; Hoos, A.; Urba, W.J. Improved survival with ipilimumab in patients with metastatic melanoma. *N. Engl. J. Med.*, **2010**, *363*(8), 711-723.

[8] Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N. Engl. J. Med.*, **2012**, *366*(26), 2443-2454.

[9] Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N. Engl. J. Med.*, **2012**, *366*(26), 2455-2465.

[10] van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; De Plaen, E.; Van den Eynde, B.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science*, **1991**, *254*(5038), 1643-1647.

[11] Türeci, O.; Sahin, U.; Schobert, I.; Koslowski, M.; Scmitt, H.; Schild, H.J.; Stenner, F.; Seitz, G.; Rammensee, H.G.; Pfreundschuh, M. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. *Cancer Res.*, **1996**, *56*(20), 4766-4772.

[12] Cheever, M.A.; Allison, J.P.; Ferris, A.S.; Finn, O.J.; Hastings, B.M.; Hecht, T.T.; Mellman, I.; Prindiville, S.A.; Viner, J.L.; Weiner, L.M.; Matrisian, L.M. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. *Clin. Cancer Res.*, **2009**, *15*(17), 5323-5337.

[13] Singh-Jasuja, H.; Emmerich, N.P.; Rammensee, H.G. The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. *Cancer Immunol. Immunother.*, **2004**, *53*(3), 187-195.

[14] Kessler, J.H.; Melief, C.J. Identification of T-cell epitopes for cancer immunotherapy. *Leukemia*, **2007**, *21*(9), 1859-1874.

[15] Hu, X.; Chakraborty, N.G.; Sporn, J.R.; Kurtzman, S.H.; Ergin, M.T.; Mukherji, B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. *Cancer Res.*, **1996**, *56*(11), 2479-2483.

[16] Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. *Nat. Med.*, **2004**, *10*(9), 909-915.

[17] Purcell, A.W.; McCluskey, J.; Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. *Nat. Rev. Drug Discov.*, **2007**, *6*(5), 404-414.

[18] Schwartzentruber, D.J.; Lawson, D.H.; Richards, J.M.; Conry, R.M.; Miller, D.M.; Treisman, J.; Gailani, F.; Riley, L.; Conlon, K.; Pockaj, B.; Kendra, K.L.; White, R.L.; Gonzalez, R.; Kuzel, T.M.; Curti, B.; Leming, P.D.; Whitman, E.D.; Balkissoon, J.; Reintgen, D.S.; Kaufman, H.; Marincola, F.M.; Merino, M.J.; Rosenberg, S.A.; Choyke, P.; Vena, D.; Hwu, P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N. Engl. J. Med.*, **2011**, *364*(22), 2119-2127.

[19] Yamada, A.; Sasada, T.; Noguchi, M.; Itoh, K. Next-generation peptide vaccines for advanced cancer. *Cancer Sci.*, **2013**, *104*(1), 15-21.

[20] Perez, S.A.; von Hofe, E.; Kallinteris, N.L.; Gritzapis, A.D.; Peoples, G.E.; Papamichail, M.; Baxevanis, C.N. A new era in anticancer peptide vaccines. *Cancer*, **2010**, *116*(9), 2071-2080.

[21] Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science*, **2011**, *331*(6024), 1565-1570.

[22] Bei, R.; Scardino, A. TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. *J. Biomed. Biotechnol.*, **2010**, *2010*, 102758.

[23] Yewdell, J.W.; Bennink, J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. *Annu. Rev. Immunol.*, **1999**, *17*, 51-88.

[24] Chen, W.; McCluskey, J. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. *Adv. Cancer Res.*, **2006**, *95*, 203-247.

[25] Itoh, K.; Yamada, A. Personalized peptide vaccines: a new therapeutic modality for cancer. *Cancer Sci.*, **2006**, *97*(10), 970-976.

[26] Mochizuki, K.; Sato, Y.; Tsuda, N.; Shomura, H.; Sakamoto, M.; Matsuura, K.; Ushijima, K.; Maeda, Y.; Katagiri, K.; Yamada, A.; Todo, S.; Kamura, T.; Harada, M.; Itoh, K. Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. *Int. J. Oncol.*, **2004**, *25*(1), 121-131.

[27] Pilla, L.; Rivoltini, L.; Patuzzo, R.; Marrari, A.; Valdagni, R.; Parmiani, G. Multipeptide vaccination in cancer patients. *Expert Opin. Biol. Ther.*, **2009**, *9*(8), 1043-1055.

[28] Nakao, M.; Shichijo, S.; Imaizumi, T.; Inoue, Y.; Matsunaga, K.; Yamada, A.; Kikuchi, M.; Tsuda, N.; Ohta, K.; Takamori, S.; Yamana, H.; Fujita, H.; Itoh, K. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. *J. Immunol.*, **2000**, *164*(5), 2565-2574.

[29] Shichijo, S.; Nakao, M.; Imai, Y.; Takasu, H.; Kawamoto, M.; Niiya, F.; Yang, D.; Toh, Y.; Yamana, H.; Itoh, K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. *J. Exp. Med.*, **1998**, *187*(3), 277-288.

[30] Harashima, N.; Tanaka, K.; Sasatomi, T.; Shimizu, K.; Miyagi, Y.; Yamada, A.; Tamura, M.; Yamana, H.; Itoh, K.; Shichijo, S. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. *Eur. J. Immunol.*, **2001**, *31*(2), 323-332.

[31] Yamada, A.; Kawano, K.; Koga, M.; Matsumoto, T.; Itoh, K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. *Cancer Res.*, **2001**, *61*(17), 6459-6466.

[32] Harada, M.; Kobayashi, K.; Matsueda, S.; Nakagawa, M.; Noguchi, M.; Itoh, K. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. *Prostate*, **2003**, *57*(2), 152-159.

[33] Inoue, Y.; Takaue, Y.; Takei, M.; Kato, K.; Kanai, S.; Harada, Y.; Tobisu, K.; Noguchi, M.; Kakizoe, T.; Itoh, K.; Wakasugi, H. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. *J. Urol.*, **2001**, *166*(4), 1508-1513.

[34] Kobayashi, K.; Noguchi, M.; Itoh, K.; Harada, M. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. *Cancer Sci.*, **2003**, *94*(7), 622-627.

[35] Yoshida, K.; Noguchi, M.; Mine, T.; Komatsu, N.; Yutani, S.; Ueno, T.; Yanagimoto, H.; Kawano, K.; Itoh, K.; Yamada, A. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. *Oncol. Rep.*, **2011**, *25*(1), 57-62.

[36] Noguchi, M.; Mine, T.; Komatsu, N.; Suekane, S.; Moriya, F.; Matsuoka, K.; Yutani, S.; Shichijo, S.; Yamada, A.; Toh, U.; Kawano, K.; Azuma, K.; Uemura, H.; Okuno, K.; Matsumoto, K.; Yanagimoto, H.; Yamanaka, R.; Oka, M.; Todo, S.; Sasada, T.; Itoh, K. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. *Cancer Biol. Ther.*, **2011**, *10*(12), 1266-1279.

[37] Avogadri, F.; Merghoub, T.; Maughan, M.F.; Hirschhorn-Cymerman, D.; Morris, J.; Ritter, E.; Olmsted, R.; Houghton, A.N.; Wolchok, J.D. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. *PLoS One*, **2010**, *5*(9), e12670.

[38] Hong, S.; Qian, J.; Li, H.; Yang, J.; Lu, Y.; Zheng, Y.; Yi, Q. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. *Cancer Immunol. Immunother.*, **2012**, *61*(4), 561-571.

[39] Melief, C.J.; van der Burg, S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. *Nat. Rev. Cancer*, **2008**, *8*(5), 351-360.

[40] Bijker, M.S.; van den Eeden, S.J.; Franken, K.L.; Melief, C.J.; Offringa, R.; van der Burg, S.H. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. *J. Immunol.*, **2007**, *179*(8), 5033-5040.

[41] Toes, R.E.; Offringa, R.; Blom, R.J.; Melief, C.J.; Kast, W.M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. *Proc. Natl. Acad. Sci. USA*, **1996**, *93*(15), 7855-7860.

[42] Kenter, G.G.; Welters, M.J.; Valentijn, A.R.; Lowik, M.J.; Berends-van der Meer, D.M.; Vloon, A.P.; Drijfhout, J.W.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; Offringa, R.; van der Burg, S.H.; Melief, C.J. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. *Clin. Cancer Res.*, **2008**, *14*(1), 169-177.

[43] Kenter, G.G.; Welters, M.J.; Valentijn, A.R.; Lowik, M.J.; Berends-van der Meer, D.M.; Vloon, A.P.; Essahsah, F.; Fathers, L.M.; Offringa, R.; Drijfhout, J.W.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; van der Burg, S.H.; Melief, C.J. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N. Engl. J. Med.*, **2009**, *361*(19), 1838-1847.

[44] Leffers, N.; Lambeck, A.J.; Gooden, M.J.; Hoogeboom, B.N.; Wolf, R.; Hamming, I.E.; Hepkema, B.G.; Willemse, P.H.; Molmans, B.H.; Hollema, H.; Drijfhout, J.W.; Sluiter, W.J.; Valentijn, A.R.; Fathers, L.M.; Oostendorp, J.; van der Zee, A.G.; Melief, C.J.; van der Burg, S.H.; Daemen, T.; Nijman, H.W. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. *Int. J. Cancer*, **2009**, *125*(9), 2104-2113.

[45] Welters, M.J.; Kenter, G.G.; Piersma, S.J.; Vloon, A.P.; Löwik, M.J.; Berends-van der Meer, D.M.; Drijfhout, J.W.; Valentijn, A.R.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; Offringa, R.; Melief, C.J.; van der Burg, S.H. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. *Clin. Cancer Res.*, **2008**, *14*(1), 178-187.

[46] Rosenberg, S.A.; Sherry, R.M.; Morton, K.E.; Yang, J.C.; Topalian, S.L.; Royal, R.E.; Kammula, U.S.; Restifo, N.P.; Hughes, M.S.; Schwarz, S.L.; Ngo, L.T.; Mavroukakis, S.A.; White, D.E. Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. *J. Immunother.*, **2006**, *29*(2), 224-231.

[47] Yajima, N.; Yamanaka, R.; Mine, T.; Tsuchiya, N.; Homma, J.; Sano, M.; Kuramoto, T.; Obata, Y.; Komatsu, N.; Arima, Y.; Yamada, A.; Shigemori, M.; Itoh, K.; Tanaka, R. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. *Clin. Cancer Res.*, **2005**, *11*(16), 5900-5911.

[48] Hida, N.; Maeda, Y.; Katagiri, K.; Takasu, H.; Harada, M.; Itoh, K. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. *Cancer Immunol. Immunother.*, **2002**, *51*(4), 219-228.

[49] Tsuda, N.; Mochizuki, K.; Harada, M.; Sukehiro, A.; Kawano, K.; Yamada, A.; Ushijima, K.; Sugiyama, T.; Nishida, T.; Yamana, H.; Itoh, K.; Kamura, T. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. *J. Immunother.*, **2004**, *27*(1), 60-72.

[50] Mine, T.; Gouhara, R.; Hida, N.; Imai, N.; Azuma, K.; Rikimaru, T.; Katagiri, K.; Nishikori, M.; Sukehiro, A.; Nakagawa, M.; Yamada, A.; Aizawa, H.; Shirouzu, K.; Itoh, K.; Yamana, H. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. *Cancer Sci.*, **2003**, *94*(6), 548-556.

[51] Tanaka, S.; Harada, M.; Mine, T.; Noguchi, M.; Gohara, R.; Azuma, K.; Tamura, M.; Yamada, A.; Morinaga, A.; Nishikori, M.; Katagiri, K.; Itoh, K.; Yamana, H.; Hashimoto, T. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. *J. Immunother.*, **2003**, *26*(4), 357-366.

[52] Sharma, P.; Wagner, K.; Wolchok, J.D.; Allison, J.P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. *Nat. Rev. Cancer*, **2011**, *11*(11), 805-812.

[53] Whiteside, T.L. Immune monitoring of clinical trials with biotherapies. *Adv. Clin. Chem.*, **2008**, *45*, 75-97.

[54] Komatsu, N.; Shichijo, S.; Nakagawa, M.; Itoh, K. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. *Scand. J. Clin. Lab. Invest.*, **2004**, *64*(6), 535-545.

[55] Mine, T.; Sato, Y.; Noguchi, M.; Sasatomi, T.; Gouhara, R.; Tsuda, N.; Tanaka, S.; Shomura, H.; Katagiri, K.; Rikimaru, T.; Shichijo, S.; Kamura, T.; Hashimoto, T.; Shirouzu, K.; Yamada, A.; Todo, S.; Itoh, K.; Yamana, H. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. *Clin. Cancer Res.*, **2004**, *10*(3), 929-937.

[56] Noguchi, M.; Uemura, H.; Naito, S.; Akaza, H.; Yamada, A.; Itoh, K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. *Prostate*, **2011**, *71*(5), 470-479.

[57] Terasaki, M.; Shibui, S.; Narita, Y.; Fujimaki, T.; Aoki, T.; Kajiwara, K.; Sawamura, Y.; Kurisu, K.; Mineta, T.; Yamada, A.; Itoh, K. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. *J. Clin. Oncol.*, **2011**, *29*(3), 337-344.

[58] Noguchi, M.; Kobayashi, K.; Suetsugu, N.; Tomiyasu, K.; Suekane, S.; Yamada, A.; Itoh, K.; Noda, S. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. *Prostate*, **2003**, *57*(1), 80-92.

[59] Noguchi, M.; Itoh, K.; Suekane, S.; Yao, A.; Suetsugu, N.; Katagiri, K.; Yamada, A.; Yamana, H.; Noda, S. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. *Cancer Sci.*, **2004**, *95*(1), 77-84.

[60] Noguchi, M.; Mine, T.; Yamada, A.; Obata, Y.; Yoshida, K.; Mizoguchi, J.; Harada, M.; Suekane, S.; Itoh, K.; Matsuoka, K. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. *Oncol. Res.*, **2007**, *16*(7), 341-349.

[61] Noguchi, M.; Kakuma, T.; Uemura, H.; Nasu, Y.; Kumon, H.; Hirao, Y.; Moriya, F.; Suekane, S.; Matsuoka, K.; Komatsu, N.; Shichijo, S.; Yamada, A.; Itoh, K. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. *Cancer Immunol. Immunother.*, **2010**, *59*(7), 1001-1009.

[62] Noguchi, M.; Moriya, F.; Suekane, S.; Matsuoka, K.; Arai, G.; Matsueda, S.; Sasada, T.; Yamada, A.; Itoh, K. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. *Prostate*, **2012**, *72*(8), 834-845.

[63] Yanagimoto, H.; Mine, T.; Yamamoto, K.; Satoi, S.; Terakawa, N.; Takahashi, K.; Nakahara, K.; Honma, S.; Tanaka, M.; Mizoguchi, J.; Yamada, A.; Oka, M.; Kamiyama, Y.; Itoh, K.; Takai, S. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. *Cancer Sci.*, **2007**, *98*(4), 605-611.

[64] Yanagimoto, H.; Shiomi, H.; Satoi, S.; Mine, T.; Toyokawa, H.; Yamamoto, T.; Tani, T.; Yamada, A.; Kwon, A.H.; Komatsu, N.; Itoh, K.; Noguchi, M. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. *Oncol. Rep.*, **2010**, *24*(3), 795-801.

[65] Burris, H.A.; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D.; Von Hoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J. Clin. Oncol.*, **1997**, *15*(6), 2403-2413.

[66] Yoshitomi, M.; Yutani, S.; Matsueda, S.; Ioji, T.; Komatsu, N.; Shichijo, S.; Yamada, A.; Itoh, K.; Sasada, T.; Kinoshita, H. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity

as possible biomarkers for patient prognosis. *Exp. Ther. Med.*, **2012**, *3*(3), 463-469.

[67] Sato, Y.; Shomura, H.; Maeda, Y.; Mine, T.; Une, Y.; Akasaka, Y.; Kondo, M.; Takahashi, S.; Shinohara, T.; Katagiri, K.; Sato, M.; Okada, S.; Matsui, K.; Yamada, A.; Yamana, H.; Itoh, K.; Todo, S. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. *Cancer Sci.*, **2003**, *94*(9), 802-808.

[68] Sato, Y.; Maeda, Y.; Shomura, H.; Sasatomi, T.; Takahashi, M.; Une, Y.; Kondo, M.; Shinohara, T.; Hida, N.; Katagiri, K.; Sato, K.; Sato, M.; Yamada, A.; Yamana, H.; Harada, M.; Itoh, K.; Todo, S. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. *Br. J. Cancer*, **2004**, *90*(7), 1334-1342.

[69] Sato, Y.; Fujiwara, T.; Mine, T.; Shomura, H.; Homma, S.; Maeda, Y.; Tokunaga, N.; Ikeda, Y.; Ishihara, Y.; Yamada, A.; Tanaka, N.; Itoh, K.; Harada, M.; Todo, S. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. *Cancer Sci.*, **2007**, *98*(7), 1113-1119.

[70] Hattori, T.; Mine, T.; Komatsu, N.; Yamada, A.; Itoh, K.; Shiozaki, H.; Okuno, K. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. *Cancer Immunol. Immunother.*, **2009**, *58*(11), 1843-1852.

[71] Yoshiyama, K.; Terazaki, Y.; Matsueda, S.; Shichijo, S.; Noguchi, M.; Yamada, A.; Mine, T.; Ioji, T.; Itoh, K.; Shirouzu, K.; Sasada, T.; Takamori, S. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. *Int. J. Oncol.*, **2012**, *40*(5), 1492-1500.

[72] Terazaki, Y.; Yoshiyama, K.; Matsueda, S.; Watanabe, N.; Kawahara, A.; Naito, Y.; Suekane, S.; Komatsu, N.; Ioji, T.; Yamada, A.; Mine, T.; Terasaki, M.; Itoh, K.; Takamori, S.; Sasada, T. Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. *Cancer Sci.*, **2012**, *103*(4), 638-644.

[73] Matsumoto, K.; Noguchi, M.; Satoh, T.; Tabata, K.; Fujita, T.; Iwamura, M.; Yamada, A.; Komatsu, N.; Baba, S.; Itoh, K. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. *BJU Int.*, **2011**, *108*(6), 831-838.

[74] Suekane, S.; Nishitani, M.; Noguchi, M.; Komohara, Y.; Kokubu, T.; Naitoh, M.; Honma, S.; Yamada, A.; Itoh, K.; Matsuoka, K.; Kanayama, H. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. *Cancer Sci.*, **2007**, *98*(12), 1965-1968.

[75] Sasada, T.; Komatsu, N.; Suekane, S.; Yamada, A.; Noguchi, M.; Itoh, K. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. *Eur. J. Cancer*, **2010**, *46*(9), 1514-1519.

[76] Eggermont, A.M. Therapeutic vaccines in solid tumours: can they be harmful? *Eur. J. Cancer*, **2009**, *45*(12), 2087-2090.

[77] Disis, M.L. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. *Cancer Immunol. Immunother.*, **2011**, *60*(3), 433-442.

[78] Hoos, A.; Eggermont, A.M.; Janetzki, S.; Hodi, F.S.; Ibrahim, R.; Anderson, A.; Humphrey, R.; Blumenstein, B.; Old, L.; Wolchok, J. Improved endpoints for cancer immunotherapy trials. *J. Natl. Cancer Inst.*, **2010**, *102*(18), 1388-1397.

[79] Amos, S.M.; Duong, C.P.; Westwood, J.A.; Ritchie, D.S.; Junghans, R.P.; Darcy, P.K.; Kershaw, M.H. Autoimmunity associated with immunotherapy of cancer. *Blood*, **2011**, *118*(3), 499-509.

[80] López, M.N.; Pereda, C.; Segal, G.; Muñoz, L.; Aguilera, R.; González, F.E.; Escobar, A.; Ginesta, A.; Reyes, D.; González, R.; Mendoza-Naranjo, A.; Larrondo, M.; Compán, A.; Ferrada, C.; Salazar-Onfray, F. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. *J. Clin. Oncol.*, **2009**, *27*(6), 945-952.

[81] Komatsu, N.; Matsueda, S.; Tashiro, K.; Ioji, T.; Shichijo, S.; Noguchi, M.; Yamada, A.; Doi, A.; Suekane, S.; Moriya, F.; Matsuoka, K.; Kuhara, S.; Itoh, K.; Sasada, T. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. *Cancer*, **2012**, *118*(12), 3208-3221.

[82] Sansone, P.; Bromberg, J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. *J. Clin. Oncol.*, **2012**, *30*(9), 1005-1014.

[83] Nishimoto, N.; Kishimoto, T. Interleukin 6: from bench to bedside. *Nat. Clin. Pract. Rheumatol.*, **2006**, *2*(11), 619-626.

[84] Kuball, J.; de Boer, K.; Wagner, E.; Wattad, M.; Antunes, E.; Weeratna, R.D.; Vicari, A.P.; Lotz, C.; van Dorp, S.; Hol, S.; Greenberg, P.D.; Heit, W.; Davis, H.L.; Theobald, M. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. *Cancer Immunol. Immunother.*, **2011**, *60*(2), 161-171.

[85] Krug, L.M.; Dao, T.; Brown, A.B.; Maslak, P.; Travis, W.; Bekele, S.; Korontsvit, T.; Zakhaleva, V.; Wolchok, J.; Yuan, J.; Li, H.; Tyson, L.; Scheinberg, D.A. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. *Cancer Immunol. Immunother.*, **2010**, *59*(10), 1467-1479.

[86] Barve, M.; Bender, J.; Senzer, N.; Cunningham, C.; Greco, F.A.; McCune, D.; Steis, R.; Khong, H.; Richards, D.; Stephenson, J.; Ganesa, P.; Nemunaitis, J.; Ishioka, G.; Pappen, B.; Nemunaitis, M.; Morse, M.; Mills, B.; Maples, P.B.; Sherman, J.; Nemunaitis, J.J. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. *J. Clin. Oncol.*, **2008**, *26*(27), 4418-4425.

[87] Slingluff, C.L.; Petroni, G.R.; Chianese-Bullock, K.A.; Smolkin, M.E.; Ross, M.I.; Haas, N.B.; von Mehren, M.; Grosh, W.W. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. *J. Clin. Oncol.*, **2011**, *29*(21), 2924-2932.

[88] Feyerabend, S.; Stevanovic, S.; Gouttefangeas, C.; Wernet, D.; Hennenlotter, J.; Bedke, J.; Dietz, K.; Pascolo, S.; Kuczyk, M.; Rammensee, H.G.; Stenzl, A. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. *Prostate*, **2009**, *69*(9), 917-927.

[89] Walter, S.; Weinschenk, T.; Stenzl, A.; Zdrojowy, R.; Pluzanska, A.; Szczylik, C.; Staehler, M.; Brugger, W.; Dietrich, P.Y.; Mendrzyk, R.; Hilf, N.; Schoor, O.; Fritsche, J.; Mahr, A.; Maurer, D.; Vass, V.; Trautwein, C.; Lewandrowski, P.; Flohr, C.; Pohla, H.; Stanczak, J.J.; Bronte, V.; Mandruzzato, S.; Biedermann, T.; Pawelec, G.; Derhovanessian, E.; Yamagishi, H.; Miki, T.; Hongo, F.; Takaha, N.; Hirakawa, K.; Tanaka, H.; Stevanovic, S.; Frisch, J.; Mayer-Mokler, A.; Kirner, A.; Rammensee, H.G.; Reinhardt, C.; Singh-Jasuja, H. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. *Nat. Med.*, **2012**, *18*(8), 1254-1261.

[90] Meyer, R.G.; Korn, S.; Micke, P.; Becker, K.; Huber, C.; Wölfel, T.; Buhl, R. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. *Lung Cancer*, **2007**, *58*(1), 88-94.

[91] Morse, M.A.; Secord, A.A.; Blackwell, K.; Hobeika, A.C.; Sinnathamby, G.; Osada, T.; Hafner, J.; Philip, M.; Clay, T.M.; Lyerly, H.K.; Philip, R. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. *Clin. Cancer Res.*, **2011**, *17*(10), 3408-3419.

[92] Holmes, J.P.; Benavides, L.C.; Gates, J.D.; Carmichael, M.G.; Hueman, M.T.; Mittendorf, E.A.; Murray, J.L.; Amin, A.; Craig, D.; von Hofe, E.; Ponniah, S.; Peoples, G.E. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. *J. Clin. Oncol.*, **2008**, *26*(20), 3426-3433.

[93] Perez, S.A.; Kallinteris, N.L.; Bisias, S.; Tzonis, P.K.; Georgakopoulou, K.; Varla-Leftherioti, M.; Papamichail, M.; Thanos, A.; von Hofe, E.; Baxevanis, C.N. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. *Clin. Cancer Res.*, **2010**, *16*(13), 3495-3506.

[94] Kallinteris, N.L.; Lu, X.; Blackwell, C.E.; von Hofe, E.; Humphreys, R.E.; Xu, M. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. *Expert Opin. Biol. Ther.*, **2006**, *6*(12), 1311-1321.

[95] Takahashi, N.; Ohkuri, T.; Homma, S.; Ohtake, J.; Wakita, D.; Togashi, Y.; Kitamura, H.; Todo, S.; Nishimura, T. First clinical

trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. *Cancer Sci.*, **2012**, *103*(1), 150-153.

[96] Zandvliet, M.L.; Kester, M.G.; van Liempt, E.; de Ru, A.H.; van Veelen, P.A.; Griffioen, M.; Guchelaar, H.J.; Falkenburg, J.H.; Meij, P. Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides. *J. Immunother.*, **2012**, *35*(2), 142-153.

[97] Speetjens, F.M.; Kuppen, P.J.; Welters, M.J.; Essahsah, F.; Voet van den Brink, A.M.; Lantrua, M.G.; Valentijn, A.R.; Oostendorp, J.; Fathers, L.M.; Nijman, H.W.; Drijfhout, J.W.; van de Velde, C.J.; Melief, C.J.; van der Burg, S.H. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. *Clin. Cancer Res.*, **2009**, *15*(3), 1086-1095.

[98] Vermeij, R.; Leffers, N.; Hoogeboom, B,N.; Hamming, I.L.; Wolf, R.; Reyners, A.K.; Molmans, B.H.; Hollema, H.; Bart, J.; Drijfhout, J.W.; Oostendorp, J.; van der Zee, A.G.; Melief, C.J.; van der Burg, S.H.; Daemen, T.; Nijman, H.W. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. *Int. J. Cancer*, **2012**, *131*(5), E670-680.

[99] Zeestraten, E.C.; Speetjens, F.M.; Welters, M.J.; Saadatmand, S.; Stynenbosch, L.F.; Jongen, R.; Kapiteijn, E.; Gelderblom, H.; Nijman, H.W.; Valentijn, A.R.; Oostendorp, J.; Fathers, L.M.; Drijfhout, J.W.; van de Velde, C.J.; Kuppen, P.J.; van der Burg, S.H.; Melief, C.J. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: A phase I/II clinical trial. *Int. J. Cancer*, **2013**, *132*(7), 1581-1591.

[100] Kakimi, K.; Isobe, M.; Uenaka, A.; Wada, H.; Sato, E.; Doki, Y.; Nakajima, J.; Seto, Y.; Yamatsuji, T.; Naomoto, Y.; Shiraishi, K.; Takigawa, N.; Kiura, K.; Tsuji, K.; Iwatsuki, K.; Oka, M.; Pan, L.; Hoffman, E.W.; Old, L.J.; Nakayama, E. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. *Int. J. Cancer*, **2011**, *129*(12), 2836-2846.

[101] Berzofsky, J.A.; Terabe, M.; Oh, S.; Belyakov, I.M.; Ahlers, J.D.; Janik, J.E.; Morris, J.C. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. *J. Clin. Invest.*, **2004**, *113*(11), 1515-1525.

[102] Pulendran, B.; Ahmed, R. Translating innate immunity into immunological memory: implications for vaccine development. *Cell*, **2006**, *124*(4), 849-863.

[103] Steinman, R.M.; Hawiger, D.; Nussenzweig, M.C. Tolerogenic dendritic cells. *Annu. Rev. Immunol.*, **2003**, *21*, 685-711.

[104] Banchereau, J.; Palucka, A.K. Dendritic cells as therapeutic vaccines against cancer. *Nat. Rev. Immunol.*, **2005**, *5*(4), 296-306.

Received: January 10, 2013 **Revised: May 24, 2013** **Accepted: May 26, 2013**

[105] Gilboa, E. DC-based cancer vaccines. *J. Clin. Invest.*, **2007**, *117*(5), 1195-1203.

[106] Reddy, S.T.; Swartz, M.A.; Hubbell, J.A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. *Trends Immunol.*, **2006**, *27*(12), 573-579.

[107] Tacken, P.J.; de Vries, I.J.; Torensma, R.; Figdor, C.G. Dendritic-cell immunotherapy: from *ex vivo* loading to *in vivo* targeting. *Nat. Rev. Immunol.*, **2007**, *7*(10), 790-802.

[108] Ferrari, M.; Downing, G. Medical nanotechnology: shortening clinical trials and regulatory pathways? *BioDrugs*, **2005**, *19*(4), 203-210.

[109] Almeida, A.J.; Souto, E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. *Adv. Drug Deliv. Rev.*, **2007**, *59*(6), 478-490.

[110] Vasir, J.K.; Labhasetwar, V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. *Adv. Drug Deliv. Rev.*, **2007**, *59*(8), 718-728.

[111] Langer, R.; Cleland, J.L.; Hanes, J. New advances in microsphere-based single-dose vaccines. *Adv. Drug Deliv. Rev.*, **1997**, *28*(1), 97-119.

[112] Shen, H.; Ackerman, A.L.; Cody, V.; Giodini, A.; Hinson, E.R.; Cresswell, P.; Edelson, R.L.; Saltzman, W.M.; Hanlon, D.J. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. *Immunology*, **2006**, *117*(1), 78-88.

[113] Zhang, Z.; Tongchusak, S.; Mizukami, Y.; Kang, Y.J.; Ioji, T.; Touma, M.; Reinhold, B.; Keskin, D.B.; Reinherz, E.L.; Sasada, T. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. *Biomaterials*, **2011**, *32*(14), 3666-3678.

[114] Noguchi, M.; Itoh, K.; Suekane, S.; Morinaga, A.; Sukehiro, A.; Suetsugu, N.; Katagiri, K.; Yamada, A.; Noda, S. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. *Prostate*, **2004**, *60*(1), 32-45.

[115] Noguchi, M.; Itoh, K.; Yao, A.; Mine, T.; Yamada, A.; Obata, Y.; Furuta, M.; Harada, M.; Suekane, S.; Matsuoka, K. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. *Prostate*, **2005**, *63*(1), 1-12.

[116] Noguchi, M.; Yao, A.; Harada, M.; Nakashima, O.; Komohara, Y.; Yamada, S.; Itoh, K.; Matsuoka, K. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. *Prostate*, **2007**, *67*(9), 933-942.

Cancer Immunol Immunother (2015) 64:493–505
DOI 10.1007/s00262-015-1660-1

ORIGINAL ARTICLE

Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression

Masanori Noguchi · Gaku Arai · Kazumasa Matsumoto · Seiji Naito · Fukuko Moriya · Shigetaka Suekane · Nobukazu Komatsu · Satoko Matsueda · Tetsuro Sasada · Akira Yamada · Tatsuyuki Kakuma · Kyogo Itoh

Received: 19 July 2014 / Accepted: 16 January 2015 / Published online: 7 February 2015
© Springer-Verlag Berlin Heidelberg 2015

Abstract The heterogeneity expression of tumor-associated antigens (TAA) and variability of human T cell repertoire suggest that effective cancer vaccine requires induction of a wide breadth of cytotoxic T lymphocyte (CTL) specificities. This can be achieved with vaccines targeting multiple TAA. We evaluated the safety and immune dynamics of a cancer vaccine consisting of 20 mixed peptides (KRM-20) designed to induce CTLs against 12 different TAA in patients with castration-resistant prostate cancer (CRPC). Patients received each of three different randomly assigned doses of KRM-20 (6, 20, or 60 mg) once a week for 6 weeks. KRM-20 was applicable for patients with positive human leukocyte antigen (HLA) A2, A3, A11, A24, A26, A31 or A33 alleles, which cover the majority of the global population. To evaluate the minimum immunological effective dose (MIED), peptide-specific CTL and immunoglobulin G (IgG) responses, and immune suppressive subsets were evaluated during the vaccination. Total of 17 patients was enrolled. No serious adverse drug reactions were encountered. The MIED of KRM-20 in CTL or IgG response calculated by logistic regression model was set as 16 or 1.6 mg, respectively. The frequency of immune suppressive subsets was fewer in the 20 mg cohort than that in 6 or 60 mg cohort. Clinical responses determined by prostate-specific antigen levels were two partial responses (from the 20 mg cohort), five no changes and ten progressive diseases. Twenty milligrams of KRM-20 could be recommended for further studies because of the safety and ability to augment CTL activity.

Keywords Cancer vaccine · Mixed peptide · Phase I · Prostate cancer · Immunotherapy

M. Noguchi (✉)
Division of Clinical Research, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
e-mail: noguchi@med.kurume-u.ac.jp

M. Noguchi · S. Suekane
Department of Urology, Kurume University School of Medicine, Kurume, Japan

G. Arai
Department of Urology, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan

K. Matsumoto
Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan

S. Naito
Department of Urology, Kyushu University Faculty of Medicine, Fukuoka, Japan

F. Moriya
Department of Pathology, Kurume University School of Medicine, Kurume, Japan

N. Komatsu · T. Sasada
Department of Immunology, Kurume University School of Medicine, Kurume, Japan

S. Matsueda · K. Itoh
Cancer Vaccine Center, Kurume University School of Medicine, Kurume, Japan

A. Yamada
Division of Cancer Vaccines, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan

T. Kakuma
Bio-Statistics Center, Kurume University School of Medicine, Kurume, Japan

Abbreviations

CR	Complete response
CRPC	Castration-resistant prostate cancer
CTL	Cytotoxic T lymphocytes
CTLA-4	Cytotoxic T lymphocyte antigen 4
ECOG	Eastern Cooperative Oncology Group
EGF-R	Epidermal growth factor receptor
HLA	Human leukocyte antigen
HNRPL	Heterogeneous nuclear ribonucleoprotein L
IgG	Immunoglobulin G
MDSC	Myeloid-derived suppressor cells
MRP3	Multidrug resistance-associated protein 3
PAP	Prostatic acid phosphatase
PBMC	Peripheral blood mononuclear cells
PD	Progressive disease
PFS	Progression-free survival
PPV	Personalized peptide vaccine
PR	Partial response
PSA	Prostate-specific antigen
PSMA	Prostate-specific membrane antigen
PTHrP	Parathyroid hormone-related peptide
SART3	Squamous cell carcinoma antigens 3
TAA	Tumor-associated antigen
T_{reg}	Regulatory T cells
UBE2 V	Ubiquitin-conjugated enzyme variant Kua
WHSC2	Wolf–Hirschhorn syndrome critical region 2

Introduction

Although numerous clinical studies of peptide-based cancer vaccines have been conducted in the past two decades, no outcome sufficient for drug approval has been obtained [1–3]. The heterogeneity of tumor-associated antigens (TAA) and the diversity of both human leukocyte antigens (HLA) and T cell subsets could hamper the successful development of therapeutic peptide vaccines [4, 5].

To overcome these hurdles, we newly developed a cancer vaccine consisting of 20 mixed peptides (KRM-20) from 12 different TAA that is applicable for patients with many different HLA alleles. These 12 TAA are highly expressed in prostate cancer tissues (prostate-specific antigen [PSA] [6], prostatic acid phosphatase [PAP] [7], prostate-specific membrane antigen [PSMA] [8], epidermal growth factor receptor [EGF-R] [9], parathyroid hormone-related peptide [PTHrP] [10]), and recognized by T cells and induced cancer-reactive CTLs (squamous cell carcinoma antigens [SART3] [11], cyclophilin B [12], Wolf–Hirschhorn syndrome critical region 2 [WHSC2] [13], UBE2V, ubiquitin-conjugated enzyme variant Kua [UBE2V] [13], heterogeneous nuclear ribonucleoprotein L [HNRPL] [13]) or having characteristics of T cell development and function ($p56^{lck}$ [14, 15], multidrug resistance-associated protein 3 [MRP3]) [15]. Twenty peptides used in this study were derived from these TAAs, and each peptide showed high immune responses to source TAA and clinical responses in previous clinical trials involving patients with CRPC [13]. All 20 peptides represent CTL epitopes, and these CTL epitopes are restricted by HLA-A2, A24, A3 supertype or A26 of major histocompatibility complex class I molecules, providing coverage of the vast majority of the general population. We also monitored regulatory T cells (T_{reg}), myeloid-derived suppressor cells (MDSC) and soluble cytotoxic T lymphocyte antigen 4 (sCTLA-4), three major types of suppressor cells for vaccine-induced CTL activity, to better understand immune dynamics during vaccination [16, 17]. We report here the results of a phase I, first-in-human study of this novel vaccine in patients with CRPC.

Patients and methods

Patient selection

Eligible patients had pathologically confirmed CRPC, age $\geq$ 20 years, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, positive status for HLA-A2, A24, A3 supertype (A3, A11, A31 and A33) or A26, life expectancy of at least 12 weeks, and adequate bone marrow function (white blood cell count $\geq$ 3,000/mm^3, lymphocyte count $\geq$ 1,000/mm^3, hemoglobin $\geq$ 8 g/dL, platelets $\geq$ 100,000/mm^3), hepatic function (total bilirubin $\leq 1.5 \times$ the upper limit of normal [ULM]) and renal function (serum creatinine $\leq 1.5 \times$ ULM). Patients were also required to have undergone bilateral orchiectomies or received ongoing treatment with a GnRH agonist or antagonist. Patients were required to have radiological progressive disease defined by computed tomography (CT), magnetic resonance imaging (MRI) or bone scan using the RECIST criteria, and/or prostate-specific antigen (PSA) progression defined as at least two consecutive rises and a level of $\geq$5 ng/ml for serum PSA taken over 2 weeks apart, in the setting of the castration level of testosterone ($\leq$50 ng/dl). Patients were excluded if they had had radiation therapy, chemotherapy, or immunotherapy within 4 weeks, immunosuppressive treatment using systemic steroid within 1 year except for using low-dose steroid (less than 30 mg/day prednisolone or less than 3 mg/day dexamethasone), multiple active cancers, a history of severe allergic reactions or severe symptoms caused by active infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, or disturbance of coagulation. Patients who had received any of the peptides within the mixture of 20 peptides (KRM-20) were also excluded.

Study design

In this phase I, open-label, multicenter, randomized, dose-ranging, first-in-human study of KRM-20 as a single agent (Clinical trial registration, UMIN000008209), patients were randomized 1:1:1 to receive 6 mg/0.15 ml (0.3 mg/peptide), 20 mg/0.5 ml (1 mg/peptide), or 60 mg/1.5 ml (3 mg/peptide) of KRM-20 subcutaneously once a week for 6 weeks. These three dose levels were chosen based on previous clinical data, in which 3 mg/peptide was considered an acceptable dose according to its safety and immunological response [18, 19]. The sample size for each cohort was 5 for the completion of protocol treatment allowing adequate evaluation of safety and tolerability while minimizing exposure to a new cancer vaccine.

The primary objective was to evaluate the safety and immunological activity of different doses of KRM-20. The immunological activity was to determine the minimum immunological effective dose (MIED) of KRM-20 among three dose levels. The MIED was calculated by logistic regression model, and the study assumption is that MIED would be $\geq$60 % of immune responses. At each dose level, immunological response rates assessed by HLA-matched peptide-specific IgG and CTL levels at pretreatment, 3 weeks (1 week after the third vaccination) and 6 weeks (1 week after the sixth vaccination), were analyzed. Secondary and exploratory endpoints included relative change in serum PSA, T_{reg}, MDSC and CTLA-4.

The study was conducted according to the Declaration of Helsinki and relevant International Conference on Harmonization Good Clinical Practice guidelines, and was notified to a Japanese regulatory agency (Pharmaceuticals and Medical Devices Agency, PMDA) and the local institutional review boards of all four participating hospitals in Japan. All participants provided written informed consent before participating in this study.

Peptide preparation and preclinical study

KRM-20 consisted of the following 20 peptides: $SART3_{302–310}$, $Lck_{246–254}$, $UBE2V_{43–51}$, $WHSC2_{141–149}$ and $HNRPL_{140–148}$ for patients with HLA-A2; $Lck_{208–216}$, $Lck_{486–494}$, $Lck_{488–497}$, $MRP3_{1293–1302}$, $PAP_{213–221}$, $PSA_{248–257}$, $PSMA_{624–632}$, $EGF\text{-}R_{800–809}$ and $PTH\text{-}rP_{102–111}$ for patients with HLA-A24; $SART3_{734–742}$, $Lck_{90–99}$ and $Lck_{449–458}$ for patients with HLA-A3 supertype; $SART3_{109–118}$ for patients with HLA-A24, A3 supertype or A26; $WHSC2_{103–111}$ for HLA-A2, A3 supertype or A26; and CypB $_{129–138}$ for patients with HLA-A2 or A3 supertype. Twenty peptides were prepared under conditions of current Good Manufacturing Practice using a Multiple Peptide System (San Diego, CA) and by the American Peptide Company (Vista, CA). The twenty peptides were mixed with incomplete Freund's adjuvant (Montanide ISA-51VG; Seppic, Paris, France) and prepared for emulsion at three different dose levels.

As KRM-20 is specific for the human host, the preclinical safety pharmacological study focused on possible effects of process-related impurities and related signs and symptoms of possible relevance for cardiovascular or respiratory in beagle, and central nervous system impairment in mice under conditions of Good Laboratory Practice (GLP). A 4-week subcutaneous subacute toxicity and 26-week chronic toxicity study in mice were also evaluated. In accordance with our previous observations [5–10], neither treatment-related deaths nor toxicologically important clinical or pathological signs were observed throughout these studies.

CTL and IgG responses

T cell responses specific to the vaccine peptides were evaluated by interferon (IFN)-γ Elispot assay (MBL, Nagoya, Japan), using peripheral blood mononuclear cells (PBMCs), which were separated by density gradient centrifugation with Ficoll-Paque Plus (GE Healthcare; Uppsala, Sweden) from peripheral blood (30 ml) before and after vaccination, and stored frozen until analysis. After thawing, PBMCs (1×10^5 cells/well) were incubated in 96-well U-bottomed plates (Thermo Fisher Scientific, Rochester, NY) with 100 μL of medium (OpTmizer™ T Cell Expansion SFM; Life Technologies, Carlsbad, CA) containing 10 % FBS (MP Biologicals, Solon, OH), 1 % L-glutamine (Life Technologies), IL-2 (20 IU/mL; AbD Serotec, Kidlington, UK) and a mixture of 20 vaccinated peptides (3 μg/mL each) for 6 days. The cultured cells were harvested and tested for their ability to produce IFN-γ in response to either the corresponding peptides or HLA-matched negative control peptides from human immunodeficiency virus (HIV) sequence (SLYNTYATL for HLA-A2; RYLRQQLLGI for HLA-A24; RLRDLLLIVTR for HLA-A3 supertype; EVIPMFSAL for HLA-A26). The cells (1×10^5 cells/well) were cultured in triplicate for 18 h at 37 °C with the C1R cells transfected with each type of HLA (1×10^4 cells/well) loaded with specific or control peptides (3 μg/mL) in a 96-well ELISPOT plate (MultiScreen, Millipore) coated with antihuman IFN-γ Ab. After washing, the spots were developed with biotin-conjugated antihuman IFN-γ Ab, streptavidin-ALP and BCIP/NBT substrate, according to the manufacturer's instructions (MBL), and then counted using an ELISPOT reader (ImmunoSpot S5 Versa Analyzer; Cellular Technology Ltd., Shaker Heights, OH). When the spot numbers in response to the specific peptides were significantly higher than those in response to the control peptides ($P < 0.05$ by Student's t test with the triplicate samples), antigen-specific CTL responses were shown

as the differences between them (means of the triplicate samples). If the spot numbers in response to at least one HLA-matched peptide per patient in the post-vaccination PBMC were more than twofold higher than those in the pre-vaccination PBMC, the changes were considered to be significant.

The humoral immune responses specific to the vaccine peptides were determined by peptide-specific IgG titers using a bead-based multiplex assay with the Luminex 200 system (Luminex, Austin, TX), as reported previously [20]. In brief, plasma before and after vaccination was incubated with 100 μL of peptide-coupled and peptide-uncoupled (negative control) color-coded beads for 1.5 h at 30 °C. After washing, the beads were incubated with 100 μL of biotinylated goat antihuman IgG Ab (gamma chain-specific; Vector Laboratories, Burlingame, CA) for 1 h at 30 °C. After washing again, the beads were incubated with 100 μL of streptavidin-PE (Life Technologies, Carlsbad, CA) for 30 min at 30 °C, followed by washing and detection of fluorescence intensity unit (FIU) on the beads using the Luminex 200 system. Peptide-specific IgG responses were defined by the difference between the FIU on peptide-coupled beads and that on peptide-uncoupled beads. If the titers of peptide-specific IgG in the post-vaccination plasma were more than twofold higher than those in the prevaccination plasma, the changes were considered to be significant. If a significant increase was observed in at least one vaccinated peptide, the specific humoral response was considered to be augmented.

T_{reg}, MDSC and sCTLA-4

T_{reg} and MDSC among the PBMC were examined by flow cytometry. For the analysis of T_{reg}, PBMC (0.5×10^6) suspended in PBS containing 2 % FBS were stained with anti-CD-4, anti-CD25 and anti-FoxP3 antibodies (Ab) by using the One Step Staining Human T_{reg} Flow™ Kit (Biolegend, San Diego, CA) in accordance with the manufacturer's instructions. For the analysis of MDSC, PBMC (0.5×10^6) suspended in PBS containing 2 % FBS were incubated with the following monoclonal Ab for 30 min at 4 °C: anti-CD3-FITC, anti-CD56-FITC, anti-CD19-FITC, anti-CD33-APC, anti-HLA-DR-PE/Cy7 and anti-CD14-APC/Cy7. In the cell subset negative for lineage markers (CD3, CD19, CD56, CD14) and HLA-DR, MDSC were identified as positive for CD33. The samples were run on a FACSCanto II (BD Biosciences, San Diego, CA), and data were analyzed using the Diva software package (BD Biosciences). The frequencies of T_{reg} and MDSC in the lymphocyte gate defined by forward scatter and side scatter were calculated. All Ab were purchased from Biolegend. sCTLA-4 in plasma was analyzed using a commercially available kit (MedSystems Diagnostics, GmbH, Vienna, Austria).

Statistical analysis

The safety and tolerability analyses were performed on data from all patients receiving at least one dose of KRM-20. Immunological analyses were performed on data from all patients who completed the study. Because of the low planned number of patients in each cohort, descriptive statistics were used to summarize all demographic, safety, tolerability and immunological outcomes by dose cohort. Changes in immunological parameters across doses were assessed by an exploratory analysis of variance.

Results

Patient population

Between June 2012 and January 2013, 17 patients from four clinical sites in Japan were randomized to treatment with KRM-20 at three different doses: Arm A (6 mg/0.15 ml), $n = 5$; Arm B (20 mg/0.5 ml), $n = 6$; and Arm C (60 mg/1.5 ml), $n = 6$. Fifteen of these 17 patients completed the study as planned, and two patients discontinued treatment due to non-treatment-related serious adverse events of compression fracture of metastatic bone or urinary retention: one in the 20 mg dose cohort (Arm B) and the other in the 60 mg dose cohort (Arm C), respectively. Demographics and baseline characteristics were generally balanced among the treatment arms, although one patient had a high PSA level in Arm A (Table 1).

Safety

Adverse events were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTC Ver. 4). There was no obvious difference in the rate of adverse events across the three dose cohorts. The most common treatment-related adverse event was skin reactions at injection sites (76.5 %). Two patients had a grade 2 increase of liver enzymes or herpes zoster. No grade 3/4 treatment-related adverse events were observed. All adverse events observed in this study are shown in Table 2.

Clinical outcomes and immune responses

All patients were assessed by CT of the abdomen and pelvis and bone scans within 4 weeks prior to the first vaccination of KRM-20, and serum PSA was evaluated at pretreatment, and after the third and sixth vaccination. Fifteen of seventeen patients completed the study treatment of six injections. According to the PSA response by the Prostate Cancer Clinical Trials Working Group (PCGW2) criteria [21], among these 15 patients, the best response was reported as a

Table 1 Patient baseline characteristics

	Arm A (6 mg/0.15 ml) ($n = 5$)	Arm B (20 mg/0.5 ml) ($n = 6$)	Arm C (60 mg/1.5 ml) ($n = 6$)	Total ($n = 17$)
Age, years				
Median	72	73.5	69	71.5
Range	60–77	68–77	55–76	55–77
ECOG performance status, *n*				
0	4	6	5	15
1	1	0	1	2
HLA typing, *n*				
A2/A3 supertype	1	2	2	5
A2/A26	0	0	1	1
A2	0	1	0	1
A24/A3 supertype	2	1	1	4
A24/A26	1	1	2	4
A24	1	0	0	1
A3 supertype	0	1	0	1
Baseline PSA, ng/ml				
Median	67.9	21.6	31.6	40.4
Range	1.02–1,529	5.23–84.8	8.72–81.47	1.02–1,529
Gleason score, *n*				
≤7	1	2	1	4
≥8	4	4	5	13
Site of metastasis, *n*				
No	0	0	1	1
Bone only	2	3	3	8
Bone and nodal/organ	1	3	2	6
Nodal / organ	2	0	0	2
Prior chemotherapy, *n*				
Estramustin phosphate	3	5	4	12
Docetaxel	2	2	3	7

ECOG Eastern Cooperative Oncology Group, *HLA* human leukocyte antigen, *PSA* prostate-specific antigen, HLA-A3 supertype including A11, A31 or A33

partial response (PR) in two patients in Arm B (20 mg dose cohort), no change (NC) in five and progressive disease (PD) in eight. Disease control (PR or NC) during the treatment was thus observed in 7 of 15 patients (Table 3).

Blood samples at pre-vaccination, and after the third and sixth vaccination in the 15 patients, were analyzed for HLA-matched peptide-specific IgG by LUMINEX and HLA-matched peptide-specific T cells by IFN-γ-based ELISPOT in a blinded fashion (Table 4). The median number of HLA-matched peptides was 10 (range 6–15) in all cases. In all HLA-matched peptides, CTL response after the third vaccination was boosted for 3 of 61, 12 of 45 and 11 of 50 peptides tested in patients receiving 6, 20 and 60 mg of KRM-20, respectively. CTL response after the sixth vaccination, however, largely decreased in patients receiving 60 mg, concomitant with strong boosting of the IgG response.

For each patient base after the sixth vaccination, CTL activity was augmented for at least one peptide in 1 of 5, 4 of 5 and 4 of 5 patients receiving 6, 20 and 60 mg of KRM-20, respectively. IgG level was also augmented in 4 of 5, 2 of 5 and all 5 patients, respectively. Collectively, 9 or 2 patients (two from the 60 mg cohort) showed boosted CTL or IgG responses after the third vaccination, while 9 or 11 patients showed this after the sixth vaccination, respectively.

Immune responses and PSA responses in 15 patients during the vaccination are shown in Fig. 1. Positive immune responses were observed in 13 of 15 patients (87 %), with 2 PR, 5 NC and 6 PD. In addition, CTL responses to two or more peptides (2–6 peptides), restricted by HLA-A2, A24, A3 supertypes or A26, were observed in 5 or 6 patients after the third or sixth vaccination.

T_{reg}, MDSC and sCTLA-4

The mean frequency of T_{reg} or MDSC among PBMC at pre-vaccination, and 3 and 6 weeks after the first vaccination were 2.0, 2.5 and 1.8 %, or 1.0, 1.2 and 1.4 %,

Table 2 Adverse events by treatment cohort and grade

	Arm A (6 mg/0.15 ml)			Arm B (20 mg/0.5 ml)			Arm C (60 mg/1.5 ml)			Total			
	$n = 5$			$n = 6$			$n = 6$			$n = 17$			
	G1	G2	G3	G1	G2	G3	G1	G2	G3	G1	G2	G3	All (%)
Any AEs													
Anemia			1									1	1 (5.9)
Toothache				1						1			1 (5.9)
Injection site skin reaction	3			5			5			13			13 (76.5)
Fever							1			1			1 (5.9)
Increased ALT and AST		1									1		1 (5.9)
Herpes zoster					1						1		1 (5.9)
Compression fracture of bone						1						1	1 (5.9)
Dehydration							1			1			1 (5.9)
Bone pain	1									1			1 (5.9)
Headache										1			1 (5.9)
Urinary retention									1			1	1 (5.9)
Microhematuria	1									1			1 (5.9)
Increased Creatinine				1						1			1 (5.9)
Treatment-related AEs													
Injection site skin reaction	3			5			5			13			13 (76.5)
Increased ALT and AST		1									1		1 (5.9)
Herpes zoster				1							1		1 (5.9)

AE adverse event, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *G* grade

Table 3 Changes of T_{reg}, MDSC and sCTLA-4, and PSA responses in 15 patients during vaccination

Patient No.	Treatment Arm	T_{reg} (%) Pre	3rd	6th	MDSC (%) Pre	3rd	6th	sCTLA-4 (ng/ml) Pre	3rd	6th	PSA response (% from base line)
1	Arm A (6 mg/0.15 ml)	2.6	2.4	**5.7**	1.6	0.2	1.2	1.5	1.4	1.3	PD (63)
2		4.9	3.2	1.7	0.5	0.4	0.2	0.0	0.0	0.0	PD (45)
3		0.9	0.7	**1.3**	0.6	0.7	0.3	0.0	0.0	0.0	PD (182)
4		1.7	2.0	**2.8**	1.9	**4.8**	0.6	0.0	0.0	0.0	NC (24.8)
5		2.6	2.9	0.9	0.8	0.5	**2.3**	0.0	0.0	0.0	NC (−2.8)
6	Arm B (20 mg/0.5 ml)	3.3	3.4	2.5	0.6	0.8	1.3	0.0	0.0	0.0	NC (11)
7		1.0	0.9	0.7	0.2	0.1	**2.2**	0.3	0.3	0.3	PR (-65)
8		2.4	3.0	0.7	1.4	**4.1**	1.2	0.0	0.0	0.0	PD (40.8)
9		0.8	0.5	**1.8**	0.3	0.4	1.0	0.0	0.0	0.0	PD (102)
10		0.8	1.5	1.1	0.8	0.7	0.8	0.0	0.0	0.0	PR (-73)
11	Arm C (60 mg/1.5 ml)	1.2	1.6	1.3	1.6	1.8	1.2	0.2	0.1	0.2	NC (2)
12		2.4	**9.6**	2.7	0.6	0.3	0.6	0.0	0.0	0.0	PD (196)
13		2.0	**2.9**	1.2	0.1	0.3	**4.1**	1.7	1.6	1.9	NC (-39)
14		2.1	**2.7**	2.0	0.8	0.8	**2.8**	0.0	0.0	0.0	PD (886)
15		1.0	1.1	1.1	3.2	1.8	0.9	0.0	0.0	0.0	PD (206)

T_{reg} regularity T cell, *MDSC* myeloid-derived suppressor cell, *Pre* pretreatment, *sCTLA-4* soluble cytotoxic T lymphocyte antigen 4, *PSA* prostate-specific antigen, *PR* partial response, *NC* no change, *PD* progressive disease

The values showing the increment are in bold

respectively (Table 3). Although there was no significant difference among these mean frequencies, it is of note that the frequency of T_{reg} after the third or sixth vaccination was increased in 3 of 5 or 3 of 5 patients receiving 60 or 6 mg of KRM-20, respectively. In contrast, the increase after the third and sixth vaccinations occurred in one patient in the

Table 4 CTL and IgG responses to HLA-matched peptides in 15 patients during vaccination

Patient no. (HLA)	HLA matching peptides (Target HLA)	CTL response (spots/$10^5\times$ cells)			IgG Response (FIU)		
		Pre	3rd	6th	Pre	3rd	6th
Arm A (6 mg/0.15 ml)							
1 (A24, A11)	CypB-129 (A11)	35	0	0	0	0	0
	EGFR-800 (A24)	0	0	0	0	0	0
	Lck-208 (A24)	0	0	0	0	0	0
	Lck-449 (A11)	0	**20**	0	14	17	13
	Lck-90 (A11)	67	36	24	31	41	**1,805**
	MRP3-1293 (A24)	0	0	0	0	0	0
	PSA-248 (A24)	0	0	0	0	0	0
	PTHrP-102 (A24)	0	0	0	0	0	0
	SART3-734 (A11)	50	17	0	5,053	6,424	5,360
	WHSC2-103 (A11)	56	0	31	11	13	11
	Lck-486 (A24)	0	0	0	15	14	13
	Lck-488 (A24)	0	0	0	20	26	21
	PSMA-624 (A24)	0	0	0	0	0	0
	PAP-213 (A24)	0	0	0	10	13	**72**
	SART3-109 (A24, A11)	76	48	0	0	**12**	**12**
2 (A2, A31)	CypB-129 (A2, A31)	72	95	90	0	0	0
	Lck-246 (A2)	0	0	**55**	0	0	0
	Lck-449 (A31)	81	65	**227**	0	10	0
	Lck-90 (A31)	128	99	99	0	0	0
	SART3-302 (A2)	0	51	0	0	0	0
	SART3-734 (A31)	139	71	88	0	0	0
	WHSC2-103 (A2, A31)	96	117	**404**	0	0	0
	HNRPL-140 (A2)	0	**36**	0	0	0	0
	SART3-109 (A31)	76	56	72	0	0	0
	WHSC2-141 (A2)	0	0	0	0	0	0
	UBE2V-43 (A2)	0	0	**25**	0	11	**19**
3 (A24, A26)	EGFR-800 (A24)	0	0	0	14	16	13
	Lck-208 (A24)	0	0	0	0	0	0
	MRP3-1293 (A24)	0	0	0	19	18	17
	PSA-248 (A24)	0	0	0	0	0	0
	PTHrP-102 (A24)	0	0	0	0	0	0
	Lck-486 (A24)	0	0	0	35	39	33
	Lck-488 (A24)	0	0	0	140	149	142
	PSMA-624 (A24)	0	0	0	19	21	18
	PAP-213 (A24)	0	0	0	12	13	11
	SART3-109 (A24, A26)	0	0	0	53	57	49
4 (A24, A31)	CypB-129 (A31)	70	0	36	0	0	0
	EGFR-800 (A24)	0	0	0	10	10	11
	Lck-208 (A24)	0	0	0	0	0	0
	Lck-449 (A31)	121	86	103	24	20	21
	Lck-90 (A31)	153	0	97	24	21	21
	MRP3-1293 (A24)	0	0	0	12	11	12
	PSA-248 (A24)	0	0	0	11	0	0
	PTHrP-102 (A24)	0	0	0	0	0	0
	SART3-734 (A31)	140	74	0	13	10	10
	WHSC2-103 (A31)	56	0	31	11	10	10

Table 4 continued

Patient no. (HLA)	HLA matching peptides (Target HLA)	CTL response (spots/$10^5\times$ cells)			IgG Response (FIU)		
		Pre	3rd	6th	Pre	3rd	6th
	Lck-486 (A24)	0	0	0	21	19	19
	Lck-488 (A24)	0	0	0	32	29	30
	PSMA-624 (A24)	0	0	0	12	0	10
	PAP-213 (A24)	0	0	0	11	10	**4,139**
	SART3-109 (A24, A31)	113	**434**	141	22	22	21
5 (A24)	EGFR-800 (A24)	0	0	0	28	27	29
	Lck-208 (A24)	0	0	0	12	14	12
	MRP3-1293 (A24)	0	0	0	37	35	34
	PSA-248 (A24)	0	0	0	60	63	**819**
	PTHrP-102 (A24)	0	0	0	0	0	0
	Lck-486 (A24)	0	0	0	60	57	53
	Lck-488 (A24)	0	0	0	118	111	108
	PSMA-624 (A24)	0	0	0	37	38	33
	PAP-213 (A24)	0	0	0	42	38	37
	SART3-109 (A24)	0	0	0	58	57	54
Response rates (confidence intervals)		0.20 (0.0051–0.7164)			0.80 (0.2836–0.9949)		
Arm B (20 mg/0.5 ml)							
6 (A2, A33)	CypB-129 (A2, A33)	0	0	0	0	0	**17**
	Lck-246 (A2)	0	**451**	**472**	0	0	0
	Lck-449 (A33)	27	0	**130**	1,004	1,127	1,064
	Lck-90 (A33)	26	44	45	66	71	68
	SART3-302 (A2)	0	0	0	1,031	1,122	1,099
	SART3-734 (A33)	31	32	**62**	81	102	102
	WHSC2-103 (A2, A33)	48	46	30	18	20	19
	HNRPL-140 (A2)	0	0	**435**	38	45	45
	SART3-109 (A33)	25	30	35	33	35	35
	WHSC2-141 (A2)	0	0	0	12	12	11
	UBE2V-43 (A2)	0	0	0	15	14	15
7 (A2)	CypB-129 (A2)	0	**107**	0	0	0	0
	Lck-246 (A2)	0	**129**	**247**	0	0	0
	SART3-302 (A2)	0	**103**	0	16	20	18
	WHSC2-103 (A2)	0	**125**	0	16	17	14
	HNRPL-140 (A2)	0	**121**	0	15	17	15
	UBE2V-43 (A2)	0	0	0	32	33	27
	WHSC2-141 (A2)	0	**121**	0	0	0	0
8 (A24, A26)	EGFR-800 (A24)	0	0	0	0	0	0
	Lck-208 (A24)	0	0	0	0	0	0
	MRP3-1293 (A24)	0	0	0	18	19	19
	PSA-248 (A24)	0	0	0	0	0	0
	PTHrP-102 (A24)	0	0	0	0	0	0
	Lck-486 (A24)	0	0	0	27	27	26
	Lck-488 (A24)	0	0	0	41	39	38
	PSMA-624 (A24)	0	0	0	11	10	11
	PAP-213 (A24)	0	0	0	0	0	0
	SART3-109 (A24, A26)	0	0	0	14	14	12
9 (A2, A33)	CypB-129 (A2, A33)	0	**45**	0	0	0	0
	Lck-246 (A2)	49	**286**	**248**	0	0	0
	Lck-449 (A33)	72	104	0	13	11	11